Lessons from Tarceva in pancreatic cancer: Where are we now, and how should future trials be designed in pancreatic cancer?

Current Opinion in Oncology

Volumn 20, Issue 4, 2008, Pages 454-458

  Laurent Puig, Pierre ^a,b,c   Taieb, Julien ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Genetic alterations; KRAS; MTOR; Mutation; Nuclear factor kB; Pancreatic cancer; PIK3CA; Targeted therapy EGFR signalling pathway

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; CELECOXIB; CETUXIMAB; CURCUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISIS 2503; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PANITUMUMAB; TEMSIROLIMUS; TRASTUZUMAB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADD ON THERAPY; ANTISENSE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL TRANSFORMATION; CHROMOSOMAL INSTABILITY; CLINICAL TRIAL; COLON CANCER; DRUG POTENTIATION; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; NONHUMAN; ONCOGENE; ONCOGENE K RAS; ONCOGENE NEU; ONCOGENE RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; DRUG ANTAGONISM; METHODOLOGY; PANCREAS TUMOR;

CLINICAL TRIALS AS TOPIC; HUMANS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH DESIGN;

EID: 47249146141     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32830218d6     Document Type: Review

References (24)

1. Croce CM. Oncogenes and cancer. N Engl J Med 2008; 358:502-511. Cancer is a DNA disease, and this recent paper gives a state of the art of the different genetic alterations of oncogenes, tumour suppressor genes and microRNA found in tumour cells and underlines the clinical importance of them in the development of rational cancer treatment.
2. Hilgers W, Kern SE. Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer 1999; 26:1-12.
3. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20:211-226.
4. Novotny J, Petruzelka L, Vedralova J, et al. Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients. Neoplasma 2001; 48:188-191.
5. Safran H, Steinhoff M, Mangray S, et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2001; 24:496-499.
6. Stoecklein NH, Luebke AM, Erbersdobler A, et al. Copy number of chromo-some 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol 2004; 22:4737-4745.
7. Shaw RJ, Cantley LC. Ras PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441:424-430.
8. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2007 [Epub ahead of print]
9. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96:1166-1169.
10. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374-379. This series of colorectal cancer patients described the prognostic role of the somatic mutation of RAS in colorectal metastatic cancer patients treated by cetuximab. This is the largest series published up to now, showing the clinical importance of the determination of KRAS status in colorectal cancer patients before treatment with an anti-EGFR targeted therapy.
11. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-3995.
12. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancer. Clin Cancer Res 2007; 13:2890-2896. This series of nonsmall-cell lung cancer shows that KRAS is an important predictor of resistance to Tarceva, a small molecule inhibitor of the tyrosine kinase domain of the EGF receptor.
13. Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol 2008; 9:39-44.
14. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-1966. This paper shows for the first time in a phase III trial the benefit of adding a targeted therapy to gemcitabine for treatment. The tested arm benefit is real but modest.
15. Kimura K, Sawada T, Komatsu M, et al. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 2006; 12:4925-4932.
16. Safran H, Iannitti D, Ramanathan R, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004; 22:706-712.
17. Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23:5281-5293.
18. Jimeno A, Rubio-Viqueira B, Amador ML, et al. Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Mol Cancer Ther 2007; 6:1079-1088. This paper underlines the importance of studying the signalling pathway in its whole in order to build an efficent strategy by combining different targeted therapies. The authors demonstrated that treatment associating an anti-EGFR with a MAPK inhibitor was more effective than either single agent alone in a pancreatic xenograft tumour model.
19. She QB, Solit DB, Ye Q, et al. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005; 8:287-297.
20. Ito D, Fujimoto K, Mori T, et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer 2006; 118:2337-2343.
21. Bremner P, Heinrich M. Natural products as targeted modulators of the nuclear factor-kappaB pathway. J Pharm Pharmacol 2002; 54:453-472.
22. Li L, Aggarwal BB, Shishodia S, et al. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004; 101:2351-2362.
23. Lev-Ari S, Vexler A, Starr A, et al. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest 2007; 25:411-418.
24. Alberts SR, Schroeder M, Erlichman C, et al. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. J Clin Oncol 2004; 22:4944-4950.